Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
about
DNA hypomethylation in cancer cells.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.Comment on "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity"Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidineLow dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesInducible expression of cancer-testis antigens in human prostate cancer.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.Improving cancer immunotherapy with DNA methyltransferase inhibitors.Epigenetic drug discovery: breaking through the immune barrier.Emerging Role for Methylation in Multiple Sclerosis: Beyond DNA.Dendritic Cell Therapies for Hematologic Malignancies.Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells.Cell-based analysis of structure-function activity of threonine aspartase 1Making a virtue of necessity: the pleiotropic role of human endogenous retroviruses in cancer.Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers
P2860
Q33862334-A2666DAA-4F8E-4619-B37C-1670A048F9EBQ34935239-86CF20E3-230C-4743-B48B-6658A5708F34Q35172875-9861C854-D1A2-4051-93E6-BEC7F36B4638Q35207569-5D9DF0D9-C2E3-43C2-A262-81B028CFB9E4Q35589288-C5F48D88-AC94-4CA7-ACDA-1ADE673BDC38Q36166026-AC297D88-78B0-4BC2-AAA1-80A2F84C2D78Q36831746-BC2B6C92-76B5-47EF-8E1F-E650AE1E6F0BQ37686238-371D70B1-D051-48BC-BE4B-2807388D1708Q37731703-408D11F0-B2E9-449E-AB26-4CE202D71763Q38588894-DDE0798B-E8A1-45A4-AFD6-6A194DB01942Q38662760-8519A51C-E7F5-4F18-B2EE-33619E5916F3Q38986705-076E4FC5-17DD-4147-B84B-12BDBC38AECAQ39288872-1580B683-A9A1-4F33-8A6B-DF3AEEB35A07Q39289930-86A53EDE-2921-400F-8469-347B32380AAFQ39546197-A1B4AB70-74ED-479D-8BC4-F218DC03F9A7Q39575992-E73EE925-7829-4BD7-9920-6B1209005F11Q39630613-AF5BA0CC-CDEE-4B32-9D17-A3E67BF0D1E4Q40046573-8C3E62BB-CF0F-4EFB-AF5A-9315351711CFQ41768675-77F6896F-E6E0-46CC-95D2-C9226EBC774B
P2860
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@en
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@nl
type
label
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@en
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@nl
prefLabel
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@en
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@nl
P2093
P1476
Treatment of chronic lymphocyt ...... nogenic cancer testis antigen.
@en
P2093
Douglas G McNeel
Eduardo M Sotomayor
Jason A Dubovsky
Javier A Pinilla-Ibarz
John Gordon
John J Powers
P304
P356
10.1158/1078-0432.CCR-08-2099
P407
P577
2009-04-28T00:00:00Z